Clover Health Investments Analyst Ratings
Clover Health Investments Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/11/2023 | 13.64% | Citigroup | $1 → $1.5 | Maintains | Neutral |
| 03/06/2023 | 127.27% | Canaccord Genuity | $4 → $3 | Maintains | Buy |
| 03/06/2023 | -5.3% | Credit Suisse | $2.5 → $1.25 | Maintains | Underperform |
| 11/16/2022 | 36.36% | Citigroup | $3.5 → $1.8 | Maintains | Neutral |
| 11/08/2022 | 13.64% | SVB Leerink | $3 → $1.5 | Maintains | Market Perform |
| 08/09/2022 | 165.15% | Citigroup | $3 → $3.5 | Maintains | Neutral |
| 08/09/2022 | 127.27% | Credit Suisse | $3.5 → $3 | Maintains | Underperform |
| 05/10/2022 | 127.27% | SVB Leerink | $2.5 → $3 | Maintains | Market Perform |
| 02/25/2022 | 89.39% | SVB Leerink | $3 → $2.5 | Maintains | Market Perform |
| 02/02/2022 | 354.55% | Canaccord Genuity | → $6 | Initiates Coverage On | → Buy |
| 02/02/2022 | 127.27% | Cowen & Co. | $7 → $3 | Upgrades | Underperform → Market Perform |
| 01/19/2022 | 127.27% | SVB Leerink | → $3 | Initiates Coverage On | → Market Perform |
| 01/07/2022 | 165.15% | Credit Suisse | $9 → $3.5 | Downgrades | Neutral → Underperform |
| 11/15/2021 | 581.82% | Credit Suisse | $8 → $9 | Maintains | Neutral |
| 09/10/2021 | 430.3% | Cowen & Co. | → $7 | Initiates Coverage On | → Underperform |
| 07/12/2021 | 581.82% | JP Morgan | → $9 | Downgrades | Neutral → Underweight |
| 06/10/2021 | 657.58% | B of A Securities | → $10 | Downgrades | Neutral → Underperform |
| 05/19/2021 | 581.82% | Credit Suisse | $10 → $9 | Maintains | Neutral |
| 05/17/2021 | 581.82% | B of A Securities | $15 → $9 | Downgrades | Buy → Neutral |
| 03/09/2021 | 657.58% | Credit Suisse | → $10 | Initiates Coverage On | → Neutral |
| 02/02/2021 | 1339.39% | Citigroup | → $19 | Initiates Coverage On | → Buy |
| 02/01/2021 | 1036.36% | JP Morgan | → $15 | Initiates Coverage On | → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/11/2023 | 13.64% | 花旗集团 | $1 → 1.5 美元 | 维护 | 中立 |
| 03/06/2023 | 127.27% | Canaccord Genu | 4 美元 → 3 美元 | 维护 | 购买 |
| 03/06/2023 | -5.3% | 瑞士信贷 | 2.5 美元 → 1.25 美元 | 维护 | 表现不佳 |
| 11/16/2022 | 36.36% | 花旗集团 | 3.5 美元 → 1.8 美元 | 维护 | 中立 |
| 2022 年 8 月 11 日 | 13.64% | SVB Leerink | $3 → 1.5 美元 | 维护 | 市场表现 |
| 08/09/2022 | 165.15% | 花旗集团 | 3 美元 → 3.5 美元 | 维护 | 中立 |
| 08/09/2022 | 127.27% | 瑞士信贷 | 3.5 美元 → 3 美元 | 维护 | 表现不佳 |
| 05/10/2022 | 127.27% | SVB Leerink | 2.5 美元 → 3 美元 | 维护 | 市场表现 |
| 2022 年 2 月 25 日 | 89.39% | SVB Leerink | $3 → 2.5 美元 | 维护 | 市场表现 |
| 02/02/2022 | 354.55% | Canaccord Genu | → 6 美元 | 启动覆盖开启 | → 购买 |
| 02/02/2022 | 127.27% | Cowen & Co. | 7 美元 → 3 美元 | 升级 | 表现不佳 → 市场表现 |
| 2022 年 1 月 19 日 | 127.27% | SVB Leerink | → 3 美元 | 启动覆盖开启 | → 市场表现 |
| 2022 年 7 月 1 日 | 165.15% | 瑞士信贷 | 9 美元 → 3.5 美元 | 降级 | 中性 → 跑赢大盘 |
| 11/15/2021 | 581.82% | 瑞士信贷 | 8 美元 → 9 美元 | 维护 | 中立 |
| 2021 年 10 月 9 日 | 430.3% | Cowen & Co. | → 7 美元 | 启动覆盖开启 | → 表现不佳 |
| 2021 年 12 月 7 日 | 581.82% | 摩根大通 | → 9 美元 | 降级 | 中性 → 体重不足 |
| 06/10/2021 | 657.58% | B of A 类证券 | → 10 美元 | 降级 | 中性 → 跑赢大盘 |
| 2021 年 5 月 19 日 | 581.82% | 瑞士信贷 | 10 美元 → 9 美元 | 维护 | 中立 |
| 05/17/2021 | 581.82% | B of A 类证券 | 15 美元 → 9 美元 | 降级 | 买入 → 中性 |
| 2021 年 9 月 3 日 | 657.58% | 瑞士信贷 | → 10 美元 | 启动覆盖开启 | → 中立 |
| 2021 年 2 月 2 日 | 1339.39% | 花旗集团 | → 19 美元 | 启动覆盖开启 | → 购买 |
| 2021 年 1 月 2 日 | 1036.36% | 摩根大通 | → 15 美元 | 启动覆盖开启 | → 中立 |
What is the target price for Clover Health Investments (CLOV)?
Clover Health Investments（CLOV）的目标价格是多少？
The latest price target for Clover Health Investments (NASDAQ: CLOV) was reported by Citigroup on August 11, 2023. The analyst firm set a price target for $1.50 expecting CLOV to rise to within 12 months (a possible 13.64% upside). 5 analyst firms have reported ratings in the last year.
花旗集团于2023年8月11日公布了Clover Health Investments（纳斯达克股票代码：CLOV）的最新目标股价。这家分析公司将目标股价定为1.50美元，预计CLOV将在12个月内升至12个月内（可能上涨13.64％）。去年有5家分析公司公布了评级。
What is the most recent analyst rating for Clover Health Investments (CLOV)?
分析师对Clover Health Investments（CLOV）的最新评级是多少？
The latest analyst rating for Clover Health Investments (NASDAQ: CLOV) was provided by Citigroup, and Clover Health Investments maintained their neutral rating.
Clover Health Investments（纳斯达克股票代码：CLOV）的最新分析师评级由花旗集团提供，三叶草健康投资维持中性评级。
When is the next analyst rating going to be posted or updated for Clover Health Investments (CLOV)?
Clover Health Investments（CLOV）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Clover Health Investments, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Clover Health Investments was filed on August 11, 2023 so you should expect the next rating to be made available sometime around August 11, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Clover Health Investments的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月进行一次评级，因此每家公司每年应该获得4个评级。Clover Health Investments的最新评级是在2023年8月11日提交的，因此您应该预计下一个评级将在2024年8月11日左右公布。
Is the Analyst Rating Clover Health Investments (CLOV) correct?
分析师对三叶草健康投资（CLOV）的评级正确吗？
While ratings are subjective and will change, the latest Clover Health Investments (CLOV) rating was a maintained with a price target of $1.00 to $1.50. The current price Clover Health Investments (CLOV) is trading at is $1.32, which is within the analyst's predicted range.
尽管评级是主观的，将会发生变化，但最新的Clover Health Investments（CLOV）评级维持不变，目标股价为1.00美元至1.50美元。Clover Health Investments（CLOV）目前的交易价格为1.32美元，在分析师的预测区间内。